vs

Side-by-side financial comparison of NETSCOUT SYSTEMS INC (NTCT) and Orthofix Medical Inc. (OFIX). Click either name above to swap in a different company.

NETSCOUT SYSTEMS INC is the larger business by last-quarter revenue ($250.7M vs $219.9M, roughly 1.1× Orthofix Medical Inc.). NETSCOUT SYSTEMS INC runs the higher net margin — 22.0% vs -1.0%, a 23.0% gap on every dollar of revenue. On growth, Orthofix Medical Inc. posted the faster year-over-year revenue change (2.0% vs -0.5%). NETSCOUT SYSTEMS INC produced more free cash flow last quarter ($59.3M vs $16.8M). Over the past eight quarters, NETSCOUT SYSTEMS INC's revenue compounded faster (11.0% CAGR vs 8.0%).

NETSCOUT Systems, Inc. is an American technology company that specializes in software observability, deep packet inspection, DDoS mitigation and AIOps. Headquartered in Westford, Massachusetts, the company was founded in 1984 by Anil Singhal and Narendra Popat, originally under the name Frontier Software.

Orthofix Medical Inc. is a global medical device firm specializing in orthopedic care. It develops, manufactures and sells spinal implants, trauma care products, bone growth stimulation therapies and regenerative medicine offerings, serving orthopedic surgeons and healthcare providers across North America, Europe and Asia Pacific.

NTCT vs OFIX — Head-to-Head

Bigger by revenue
NTCT
NTCT
1.1× larger
NTCT
$250.7M
$219.9M
OFIX
Growing faster (revenue YoY)
OFIX
OFIX
+2.5% gap
OFIX
2.0%
-0.5%
NTCT
Higher net margin
NTCT
NTCT
23.0% more per $
NTCT
22.0%
-1.0%
OFIX
More free cash flow
NTCT
NTCT
$42.4M more FCF
NTCT
$59.3M
$16.8M
OFIX
Faster 2-yr revenue CAGR
NTCT
NTCT
Annualised
NTCT
11.0%
8.0%
OFIX

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
NTCT
NTCT
OFIX
OFIX
Revenue
$250.7M
$219.9M
Net Profit
$55.1M
$-2.2M
Gross Margin
81.6%
71.1%
Operating Margin
25.7%
0.2%
Net Margin
22.0%
-1.0%
Revenue YoY
-0.5%
2.0%
Net Profit YoY
13.0%
92.4%
EPS (diluted)
$0.75
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NTCT
NTCT
OFIX
OFIX
Q4 25
$250.7M
$219.9M
Q3 25
$219.0M
$205.6M
Q2 25
$186.7M
$203.1M
Q1 25
$205.0M
$193.6M
Q4 24
$252.0M
$215.7M
Q3 24
$191.1M
$196.6M
Q2 24
$174.6M
$198.6M
Q1 24
$203.4M
$188.6M
Net Profit
NTCT
NTCT
OFIX
OFIX
Q4 25
$55.1M
$-2.2M
Q3 25
$25.8M
$-22.8M
Q2 25
$-3.7M
$-14.1M
Q1 25
$18.6M
$-53.1M
Q4 24
$48.8M
$-29.1M
Q3 24
$9.0M
$-27.4M
Q2 24
$-443.4M
$-33.4M
Q1 24
$-32.4M
$-36.0M
Gross Margin
NTCT
NTCT
OFIX
OFIX
Q4 25
81.6%
71.1%
Q3 25
80.1%
72.2%
Q2 25
76.7%
68.7%
Q1 25
77.7%
62.8%
Q4 24
81.5%
69.0%
Q3 24
78.0%
68.7%
Q2 24
74.6%
67.8%
Q1 24
75.3%
67.5%
Operating Margin
NTCT
NTCT
OFIX
OFIX
Q4 25
25.7%
0.2%
Q3 25
14.8%
-8.3%
Q2 25
-3.5%
-7.9%
Q1 25
9.7%
-25.2%
Q4 24
24.5%
-5.3%
Q3 24
7.4%
-9.6%
Q2 24
-265.4%
-12.5%
Q1 24
-18.2%
-15.6%
Net Margin
NTCT
NTCT
OFIX
OFIX
Q4 25
22.0%
-1.0%
Q3 25
11.8%
-11.1%
Q2 25
-2.0%
-6.9%
Q1 25
9.1%
-27.4%
Q4 24
19.4%
-13.5%
Q3 24
4.7%
-13.9%
Q2 24
-254.0%
-16.8%
Q1 24
-15.9%
-19.1%
EPS (diluted)
NTCT
NTCT
OFIX
OFIX
Q4 25
$0.75
$-0.05
Q3 25
$0.35
$-0.57
Q2 25
$-0.05
$-0.36
Q1 25
$0.28
$-1.35
Q4 24
$0.67
$-0.76
Q3 24
$0.13
$-0.71
Q2 24
$-6.20
$-0.88
Q1 24
$-0.43
$-0.95

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NTCT
NTCT
OFIX
OFIX
Cash + ST InvestmentsLiquidity on hand
$540.6M
$82.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.6B
$450.0M
Total Assets
$2.3B
$850.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NTCT
NTCT
OFIX
OFIX
Q4 25
$540.6M
$82.0M
Q3 25
$483.4M
$62.9M
Q2 25
$489.6M
$65.6M
Q1 25
$457.4M
$58.0M
Q4 24
$398.4M
$83.2M
Q3 24
$363.4M
$30.1M
Q2 24
$362.2M
$26.4M
Q1 24
$389.7M
$27.0M
Total Debt
NTCT
NTCT
OFIX
OFIX
Q4 25
Q3 25
$157.2M
Q2 25
$157.0M
Q1 25
$156.9M
Q4 24
$157.0M
Q3 24
$118.5M
Q2 24
$118.0M
Q1 24
$118.2M
Stockholders' Equity
NTCT
NTCT
OFIX
OFIX
Q4 25
$1.6B
$450.0M
Q3 25
$1.6B
$442.5M
Q2 25
$1.5B
$458.3M
Q1 25
$1.6B
$458.3M
Q4 24
$1.5B
$503.1M
Q3 24
$1.5B
$525.9M
Q2 24
$1.4B
$546.0M
Q1 24
$1.9B
$570.3M
Total Assets
NTCT
NTCT
OFIX
OFIX
Q4 25
$2.3B
$850.6M
Q3 25
$2.2B
$832.6M
Q2 25
$2.2B
$837.2M
Q1 25
$2.2B
$823.1M
Q4 24
$2.2B
$893.3M
Q3 24
$2.1B
$867.9M
Q2 24
$2.1B
$882.0M
Q1 24
$2.6B
$906.0M
Debt / Equity
NTCT
NTCT
OFIX
OFIX
Q4 25
Q3 25
0.36×
Q2 25
0.34×
Q1 25
0.34×
Q4 24
0.31×
Q3 24
0.23×
Q2 24
0.22×
Q1 24
0.21×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NTCT
NTCT
OFIX
OFIX
Operating Cash FlowLast quarter
$62.1M
$27.7M
Free Cash FlowOCF − Capex
$59.3M
$16.8M
FCF MarginFCF / Revenue
23.6%
7.6%
Capex IntensityCapex / Revenue
1.1%
4.9%
Cash ConversionOCF / Net Profit
1.13×
TTM Free Cash FlowTrailing 4 quarters
$275.5M
$-1.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NTCT
NTCT
OFIX
OFIX
Q4 25
$62.1M
$27.7M
Q3 25
$6.7M
$12.4M
Q2 25
$73.6M
$11.6M
Q1 25
$141.5M
$-18.4M
Q4 24
$41.5M
$23.7M
Q3 24
$-3.7M
$11.7M
Q2 24
$38.4M
$9.0M
Q1 24
$93.6M
$-18.6M
Free Cash Flow
NTCT
NTCT
OFIX
OFIX
Q4 25
$59.3M
$16.8M
Q3 25
$4.4M
$2.5M
Q2 25
$71.7M
$4.5M
Q1 25
$140.1M
$-25.1M
Q4 24
$39.6M
$15.2M
Q3 24
$-4.6M
$6.3M
Q2 24
$37.2M
$-360.0K
Q1 24
$92.0M
$-29.1M
FCF Margin
NTCT
NTCT
OFIX
OFIX
Q4 25
23.6%
7.6%
Q3 25
2.0%
1.2%
Q2 25
38.4%
2.2%
Q1 25
68.4%
-13.0%
Q4 24
15.7%
7.0%
Q3 24
-2.4%
3.2%
Q2 24
21.3%
-0.2%
Q1 24
45.2%
-15.4%
Capex Intensity
NTCT
NTCT
OFIX
OFIX
Q4 25
1.1%
4.9%
Q3 25
1.0%
4.8%
Q2 25
1.0%
3.5%
Q1 25
0.7%
3.5%
Q4 24
0.7%
4.0%
Q3 24
0.5%
2.7%
Q2 24
0.7%
4.7%
Q1 24
0.8%
5.6%
Cash Conversion
NTCT
NTCT
OFIX
OFIX
Q4 25
1.13×
Q3 25
0.26×
Q2 25
Q1 25
7.60×
Q4 24
0.85×
Q3 24
-0.41×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NTCT
NTCT

Services$129.0M51%
Products$121.7M49%

OFIX
OFIX

Spinal Implants Biologics And Enabling Technologies$113.6M52%
Bone Growth Therapies$68.3M31%
Other$22.7M10%
IT$5.9M3%
GB$3.5M2%
FR$3.5M2%
DE$2.3M1%

Related Comparisons